| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $161,971,372 | +$38,464,806 | 11,162,741 | +31% | Fairmount Funds Management LLC | 17 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | -11% | $94,411,973 | +$14,637,703 | 4,909,619 | +18% | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
| BlackRock, Inc. | 6.6% | +42% | $96,248,890 | +$29,642,149 | 3,175,483 | +45% | BlackRock, Inc. | 31 Dec 2025 |
| VIKING GLOBAL INVESTORS LP | 5.5% | $38,693,672 | 2,666,690 | VIKING GLOBAL INVESTORS LP | 17 Sep 2025 | |||
| VANGUARD GROUP INC | 5.1% | $74,366,494 | 2,453,530 | The Vanguard Group | 31 Dec 2025 | |||
| Deep Track Capital, LP | 4.5% | -12% | $65,515,368 | +$8,023,966 | 2,161,510 | +14% | Deep Track Capital, LP | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 4.3% | -18% | $62,382,466 | +$3,409,845 | 2,058,148 | +5.8% | RTW Investments, LP | 31 Dec 2025 |
As of 31 Dec 2025, 141 institutional investors reported holding 52,849,512 shares of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value (ORKA). This represents 110% of the company’s total 47,863,907 outstanding shares.
The largest institutional shareholders of Oruka Therapeutics, Inc. - Common Stock, $0.001 par value (ORKA) together control 96% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 7,261,384 | +0.05% | 0.01% | $220,092,549 |
| VR ADVISER, LLC | 8.7% | 4,148,428 | 0% | 6.2% | $125,738,853 |
| Fairmount Funds Management LLC | 7.7% | 3,705,262 | 0% | 8.5% | $112,306,491 |
| BlackRock, Inc. | 7.4% | 3,539,415 | +61% | 0% | $107,279,669 |
| VIKING GLOBAL INVESTORS LP | 5.6% | 2,666,690 | 0% | 0.21% | $80,827,374 |
| VANGUARD GROUP INC | 5.1% | 2,453,530 | +38% | 0% | $74,366,494 |
| Deep Track Capital, LP | 4.5% | 2,161,510 | -19% | 1.5% | $65,515,368 |
| RTW INVESTMENTS, LP | 4.3% | 2,058,148 | +5.8% | 0.62% | $62,382,466 |
| Commodore Capital LP | 3.7% | 1,753,054 | 0% | 3.5% | $53,135,067 |
| Paradigm Biocapital Advisors LP | 3.6% | 1,710,316 | 1.4% | $51,839,678 | |
| Remedium Capital Partners, LLC | 3.2% | 1,552,414 | 0% | 28% | $47,054,000 |
| PERCEPTIVE ADVISORS LLC | 3.1% | 1,476,501 | +16% | 0.82% | $44,752,745 |
| STATE STREET CORP | 2.9% | 1,383,847 | +112% | 0% | $41,944,403 |
| Avoro Capital Advisors LLC | 2.8% | 1,333,340 | 0% | 0.4% | $40,413,535 |
| Blackstone Inc. | 2.4% | 1,165,408 | +37% | 0.15% | $35,323,516 |
| Polar Capital Holdings Plc | 2% | 978,288 | -5.2% | 0.14% | $29,651,909 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 942,507 | +37% | 0% | $28,574,387 |
| FRANKLIN RESOURCES INC | 2% | 938,421 | -12% | 0.01% | $28,443,541 |
| Affinity Asset Advisors, LLC | 1.7% | 802,342 | -16% | 1.7% | $24,318,986 |
| MERCER GLOBAL ADVISORS INC /ADV | 1.6% | 745,277 | -13% | 0.03% | $22,589,346 |
| CITADEL ADVISORS LLC | 1.5% | 726,118 | +129% | 0.01% | $22,008,637 |
| Avidity Partners Management LP | 1.4% | 660,424 | 0% | 5.8% | $20,017,451 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 649,346 | +3.6% | 0% | $19,683,000 |
| Point72 Asset Management, L.P. | 1.3% | 600,000 | -42% | 0.03% | $18,186,000 |
| Woodline Partners LP | 1.2% | 574,553 | +0.04% | 0.07% | $17,414,701 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 52,849,512 | $1,601,909,476 | +$170,659,397 | $30.31 | 141 |
| 2025 Q3 | 45,557,412 | $875,823,009 | +$220,884,566 | $19.23 | 104 |
| 2025 Q2 | 34,429,035 | $385,950,468 | +$30,431,109 | $11.21 | 81 |
| 2025 Q1 | 31,776,517 | $326,087,518 | -$21,453,560 | $10.26 | 70 |
| 2024 Q4 | 31,038,311 | $606,624,310 | +$125,781,752 | $19.39 | 66 |
| 2024 Q3 | 24,559,501 | $604,174,991 | +$603,646,384 | $24.51 | 41 |